Bortezomib increased TMZ toxicity in GBM cell lines, and it was accompanied by the stabilization of the IκB protein, acting as an NFκB inhibitor, which resulted in lower levels of nuclear NFκB and MGMT protein expression [38]. Here, NFKB1 is linked to glioblastoma.